Navigation Links
Published Study Shows More Patients See Improvement in Overactive Bladder Symptoms With Urgent(R) PC Device Compared to Those Using a Drug
Date:9/3/2009

female with an average age of 58 years, and an average history of OAB duration of more than 9 years.

"PTNS may be considered a clinically significant alternative to pharmacologic therapy for the treatment of OAB with statistically significant improvements in patient self-assessments compared to drugs, and comparable objective effectiveness," said Dr. Kenneth M. Peters, the primary author, and Chairman of the Department of Urology at Beaumont Hospital in Royal Oak, Michigan. "PTNS represents an important addition to our therapeutic armamentarium."

Dr. Peters led the 12-week OrBIT (Overactive Bladder Innovative Therapy) multi-center trial, on which the article "Randomized Trial of Percutaneous Tibial Nerve Stimulation Versus Extended-Release Tolterodine: Results From the Overactive Bladder Innovative Therapy Trial" is based.

The results confirm that Urgent PC's PTNS reduces the incidence of voiding episodes at a rate comparable to extended-release tolterodine, known by the trade name Detrol(R) LA (Pfizer), the leading pharmaceutical therapy for OAB, and that patients report a statistically significant decrease in their overall OAB symptoms compared to patients on extended-release tolterodine.

The study of 100 patients was conducted in 11 U.S. centers. These patients were randomized to either PTNS treatment with Urgent PC, or to extended-release tolterodine. All patients in the study were diagnosed with urinary frequency at eight or more voids per day. Patients randomized into the PTNS treatment were treated weekly for 12 consecutive weeks, while patients randomized into the pharmacologic therapy were given a 90-day prescription of 4 mg daily. All patients completed voiding and bladder control diaries and questionnaires at baseline and after completion of 12 weeks of treatment.


'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Recently Published Study Demonstrates Pharmacokinetic Advantages of ENDOMETRIN(R) Over Crinone(R) for Progesterone Supplementation
2. ANAVEX reports sigma receptor review published in leading journal
3. PLC Announces That Initial Abstract for Presentation of CCM Study of RenalGuard(R) at ESC 2009 Has Been Published; Strong Preliminary Results Seen
4. Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination
5. New Published Diet Study Reveals Meal Replacements as Top Strategy for Weight Loss
6. Noted Vertebroplasty Expert Cites Concerns About Recently Published Study
7. Latest Holiday Migraine Survey Results Published
8. Top Dermatologists to be Selected and Published in "The Leading Physicians of the World" Consumer Directory.
9. Human Pheromones: Whats Purported, Whats Supported - A White Paper Published by The Sense of Smell Institute
10. ACC Responds to Study Published in Pediatrics About Phthalate and IV Tubing
11. CIFOR Guidelines for Foodborne Disease Outbreak Response Published by National Food Safety Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 PrettySkin4Less announces it is ... serums by top skin care manufacturer EMINENCE to ... of vitamins, minerals and active organic ingredients to promote ... many other beauty products offer. For this reason it’s ... , "I like products that do what they ...
(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... As Januvia lawsuit ... in courts throughout the U.S., Bernstein Liebhard LLP notes ... held a meeting to discuss the safety of Januvia ... According to a June 12th report from Bloomberg.com, the ... Januvia and similar drugs, following a recent study that ...
(Date:6/19/2013)... is believed to be the largest follow-up record of ... a movement disorder that can cause crippling muscle ... success rates and lasting benefits. , Michele Tagliati, MD, ... Medical Center,s Department of Neurology, and Ron L. Alterman, ... Israel Deaconess Medical Center in Boston, published the study ...
(Date:6/19/2013)... study reveals significant disparities between minority and white ... treatment programs. Moreover, these disparities vary widely from ... that for most states there,s something amiss," says ... biostatistics. "There are strong racial and ethnic disparities ... abuse treatment programs successfully, and those disparities are ...
Breaking Medicine News(10 mins):Health News:PrettySkin4Less Launches New Innovative Skin Serums with Active Organic Ingredients to World Wide Consumer Base 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3
... PharmaTech (Cayman) Inc.,(NYSE: WX ), a leading ... with operations in China and the,United States, today announced ... WuXi PharmaTech Board of Directors. , ... Dr. Ge Li, WuXi,s Chairman and Chief ...
... Receptors and Cell Signaling at UH and MethodistHOUSTON, Feb. ... of a $5.5 million grant to the University ... (ETF). As a result of the ETF grant, UH ... to carry out laboratory research and to create next-generation ...
... today for the event to take place November 21-22 ... 5 The Leukemia & Lymphoma Society (LLS) and ... officials, announcement today granting the two organizations permission to ... November 21-22, 2009. The event, Women,s Running ...
... W.Va., Feb. 5 ReBuilder Medical Technologies, Inc. (Pink ... treatments for diabetic peripheral neuropathy and ... increase in sales for the month of January. (Logo: ... appear to be recession proof and this monthly sales ...
... unemployment rate facing Americans with disabilities , WASHINGTON, Feb. ... the first time, release employment and unemployment data on ... information will assist the nation in understanding how changing ... it is widely believed that this group typically faces ...
... February 5, 2009 Narcotics have an irreversible effect ... illness, according to Dr. Stphane Potvin of the Universit ... Louis-H Lafontaine Hospital. , According to his research, ... suffer from drug addiction. The study has shown that ...
Cached Medicine News:Health News:WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board 2Health News:WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board 3Health News:Internationally Acclaimed Researcher Joins UH Faculty 2Health News:Internationally Acclaimed Researcher Joins UH Faculty 3Health News:Internationally Acclaimed Researcher Joins UH Faculty 4Health News:Internationally Acclaimed Researcher Joins UH Faculty 5Health News:Internationally Acclaimed Researcher Joins UH Faculty 6Health News:The Leukemia & Lymphoma Society and Women's Running Magazine Join Forces to Launch New All-Women Half Marathon in St. Petersburg 2Health News:ReBuilder Medical Technologies, Inc. (RBRM) Announces Sales Increase In Jan. 09 2Health News:U.S. Labor Department to begin new monthly data series on people with disabilities from Current Population Survey on Feb. 6 2
(Date:6/19/2013)...  Haemonetics Corporation (NYSE: HAE ) ... of its previously announced manufacturing transformation.  ... , Haemonetics has selected Sanmina Corporation (NASDAQ: ... medical devices currently manufactured in Braintree ... of integrated manufacturing solutions, components, products and repair, ...
(Date:6/19/2013)... Dr. Davis Lee , CMIO for PIH Health ... 2013 AMDIS Award, a prestigious recognition saluting excellence and ... "On behalf of Allscripts, I,d like to congratulate Dr. ... efforts to improve patient care and population health," said ... Officer of Allscripts. "We are committed to our partnership ...
(Date:6/19/2013)... , June 19, 2013 The American Association ... from Maryland , announced today the filing ... Washington, D.C. , asking that the scheduled ... for durable medical equipment (DME) be stopped because of serious ... Health and Human Services (HHS) Secretary Kathleen Sebelius ...
Breaking Medicine Technology:Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 2Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 3Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 4Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 5AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 2AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 3AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 4AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 5
... After Ozarelix Was Maintained For ... Up To Six Months, ... Thereafter, IRVINE, Calif., Sept. 5 Spectrum,Pharmaceuticals, Inc., (Nasdaq: SPPI ... Company,s drug candidate for the,treatment of benign prostatic hypertrophy (BPH), at the ...
... Hosts Key Investigator Meeting for European Participants in ... 3 AGENDA Trial Targeting Biomarker-Defined Population, ... (Nasdaq: GNTA ) announced that data from ... plus chemotherapy would be,presented at the opening session ...
Cached Medicine Technology:Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 2Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 3Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 4Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie 5Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 2Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 3Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 4Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology 5
... is an FDA approved rapid ... blood test used to aid ... infection. This CLIA waived test, ... antibodies to HIV-1, requires only ...
... The Acceava Mononucleosis test provides ... Mononucleosis with a simple procedure that ... Side-by-side evaluations with competitive products will ... These attributes enable you to deliver ...
Unitary one step immuno-chromatographic assay for the qualitative detection of infectious mononucleosis heterophile antibodies in human serum, plasma or whole blood....
... Influenza A+B test allows for the ... A and type B antigens directly ... nasal aspirate specimens. The test is ... rapid differential diagnosis of acute influenza ...
Medicine Products: